Drug therapy for acute myocardial infarction at Hospital de Clínicas de Porto Alegre

OBJETIVO: Determinar a taxa de prescrição de trombolíticos, aspirina, betabloqueadores e inibidores da enzima conversora da angiotensina na fase aguda do infarto e, no caso dos três últimos fármacos citados, na profilaxia secundária do infarto agudo do miocárdio. MATERIAIS E MÉTODOS: As taxas de prescrição foram determinadas mediante revisão de prontuários de todos os pacientes que estiveram internados com o diagnóstico de infarto agudo do miocárdio no Hospital de Clínicas de Porto Alegre entre janeiro de 1996 e fevereiro de 1997. RESULTADOS: Foram identificados 100 pacientes, com uma idade média de 63 ± 13 anos, 58% homens e 89% brancos. As taxas de prescrição dos fármacos na fase aguda foram: 41% para trombolíticos, 97% para aspirina, 81% para betabloqueadores e 38% para inibidores da enzima conversora. As taxas de prescrição na profilaxia secundária foram: 71% para aspirina, 68% para beta-bloqueadores e 45% para inibidores da enzima conversora. CONCLUSÃO: As taxas de prescrição dos fármacos acima citados ainda encontramse abaixo dos valores ideais, apesar de serem comparáveis às taxas relatadas na literatura.OBJECTIVE: To determine the prescription rates of thrombolytics, aspirin, betaadrenergic antagonists and angiotensin-converting-enzyme inhibitors during the acute phase of the infarction, and to determine the prescription rates of aspirin, betaadrenergic antagonists, and angiotensin-converting-enzyme inhibitors for secondary prophylaxis. MATERIALS AND METHODS: The prescription rates were determined by reviewing the medical records of all patients whose diagnosis of acute myocardial infarction was made at Hospital de Clínicas de Porto Alegre from January 1996 to February 1997. RESULTS: We identified 100 patients, with a mean age of 63 ± 13 years, 58% men and 89% white. The drug prescription rates in the acute phase were: 41% for thrombolytics, 97% for aspirin, 81% for beta-adrenergic antagonists and 38% for angiotensin-converting-enzyme inhibitors. The secondary prophylaxis prescription rates were: 71% for aspirin, 68% for beta-adrenergic antagonists and 45% for angiotensin-converting-enzyme inhibitors. CONCLUSION: The prescripition rates forthe drugs listed above are still bellow the ideal ranges, although they are comparable to the rates reported in the medical literature

Tratamento medicamentoso do infarto agudo do miocárdio no Hospital de Clínicas de Porto Alegre

OBJECTIVE: To determine the prescription rates of thrombolytics, aspirin, betaadrenergic antagonists and angiotensin-converting-enzyme inhibitors during the acutephase of the infarction, and to determine the prescription rates of aspirin, betaadrenergic antagonists, and angiotensin-converting-enzyme inhibitors for secondaryprophylaxis.MATERIALS AND METHODS: The prescription rates were determined by reviewing the medical records of all patients whose diagnosis of acute myocardial infarctionwas made at Hospital de Clínicas de Porto Alegre from January 1996 to February 1997.RESULTS: We identified 100 patients, with a mean age of 63 ± 13 years, 58% men and 89% white. The drug prescription rates in the acute phase were: 41% forthrombolytics, 97% for aspirin, 81% for beta-adrenergic antagonists and 38% for angiotensin-converting-enzyme inhibitors. The secondary prophylaxis prescriptionrates were: 71% for aspirin, 68% for beta-adrenergic antagonists and 45% for angiotensin-converting-enzyme inhibitors.CONCLUSION: The prescripition rates forthe drugs listed above are still bellow the ideal ranges, although they are comparable to the rates reported in the medicalliterature.OBJETIVO: Determinar a taxa de prescrição de trombolíticos, aspirina, betabloqueadores e inibidores da enzima conversora da angiotensina na fase aguda doinfarto e, no caso dos três últimos fármacos citados, na profilaxia secundária do infarto agudo do miocárdio.MATERIAIS E MÉTODOS: As taxas de prescrição foram determinadas mediante revisão de prontuários de todos os pacientes que estiveram internados com odiagnóstico de infarto agudo do miocárdio no Hospital de Clínicas de Porto Alegre entre janeiro de 1996 e fevereiro de 1997.RESULTADOS: Foram identificados 100 pacientes, com uma idade média de 63 ± 13 anos, 58% homens e 89% brancos. As taxas de prescrição dos fármacos nafase aguda foram: 41% para trombolíticos, 97% para aspirina, 81% para betabloqueadores e 38% para inibidores da enzima conversora. As taxas de prescriçãona profilaxia secundária foram: 71% para aspirina, 68% para beta-bloqueadores e 45% para inibidores da enzima conversora.CONCLUSÃO: As taxas de prescrição dos fármacos acima citados ainda encontramse abaixo dos valores ideais, apesar de serem comparáveis às taxas relatadas na literatura

Estudo da proteína S100B na doença de Parkinson e no parkinsonismo atípico

25

Tracker Operation and Performance at the Magnet Test and Cosmic Challenge

During summer 2006 a fraction of the CMS silicon strip tracker was operated in a comprehensive slice test called the Magnet Test and Cosmic Challenge (MTCC). At the MTCC, cosmic rays detected in the muon chambers were used to trigger the readout of all CMS sub-detectors in the general data acquisition system and in the presence of the 4 T magnetic field produced by the CMS superconducting solenoid. This document describes the operation of the Tracker hardware and software prior, during and after data taking. The performance of the detector as resulting from the MTCC data analysis is also presented

Avaliação do componente P50 do potencial evocado auditivo em pacientes com doença de Parkinson

Resumo não disponíve

Avaliação do componente P50 do potencial evocado auditivo em pacientes com doença de Parkinson

Resumo não disponíve